VitroGel® RGD played a key role in preserving tumor architecture for effective drug testing in lymphoma research. Hydrogel:VitroGel® RGD (Cat. No: TWG003) VitroGel® played a The fight against cancer, particularly B-cell lymphomas, is challenged by the complexity of tumor microenvironments and the need for personalized treatment strategies. Traditional models such as cell lines and xenografts […]
VitroGel® significantly enhanced the delivery of dexamethasone to the inner ear, providing controlled release and improved protection against cisplatin-induced hearing loss. Hydrogel: VitroGel® RGD (Cat. No: TWG003) VitroGel® played a crucial role in the study by enhancing the local delivery of dexamethasone (Dexa) to the inner ear. It facilitated a controlled and prolonged release of […]
VitroGel® revolutionizes colorectal cancer research by creating a xeno-free platform for patient-derived organoids, enabling groundbreaking insights into tumor-immune interactions and immunotherapy responses. Hydrogel:VitroGel® MSC (Cat. No: VHM03) Other VitroGel® option:VitroGel® ORGANOID-3 (Cat. No: VHM04-3) VitroGel® played a crucial role in establishing a patient-derived immunity-organoid interaction platform for colorectal cancer (CRC) research. By providing a xeno-free […]
VitroGel® ORGANOID empowered breakthrough single-cell pharmacotranscriptomic profiling by enabling robust, patient-specific cancer organoid models for drug discovery and resistance analysis. Hydrogel:VitroGel® ORGANOID-4 (Cat. No: VHM04-4) In this study, Dini et al. present a high-throughput pharmacotranscriptomic pipeline utilizing live-cell barcoding and single-cell RNA sequencing (scRNA-Seq) to analyze drug response mechanisms and resistance pathways in high-grade serous […]
VitroGel® ORGANOID-4 deepened ovarian cancer research by allowing 3D spheroid formation and transcriptomic analysis, identifying key signaling STAT1 and GREM1 activation pathways. Institutions:University of Oulu; Institute for Molecular Medicine Finland; University of Helsinki; Tampere University Hospital and Faculty of Medicine and Health Technology; Okayama University Graduate School of Medicine; Karolinska Institutet. Team:Emilia Piki, Alice Dini, […]
VitroGel® Hydrogel for Ex Vivo/Tissue Explant Models Lymphomoids: A Tissue-based Ex Vivo Culture System for Lymphoma Therapy Screening
2024 in Review: TheWell Bioscience Milestones, Growth, and Vision for 2025 We’re excited to celebrate the milestones that defined this remarkable year. We extend our heartfelt gratitude to all the researchers, collaborators, and partners who have supported us in advancing VitroGel® for 3D cell culture, driving innovation in biomedicine and beyond.
2024 Innovations for Advancing 3D Cell Culture This year has marked remarkable growth and innovation for TheWell Bioscience. We introduced groundbreaking products, including the VitroGel® Invasion Assay Kits, VitroGel® Starter Kits, VitroPrime Cell Culture Inserts, and VitroPrime Spread-Attach Plate. These innovations further enhance our comprehensive workflow for full lab automation, empowering researchers to achieve greater […]
VitroGel® Hydrogel Matrix provided a realistic three-dimensional environment for studying Glioblastoma invasion behavior. Institution:Department of Biological Science, Chungnam National University Team:Jiyoon Baik, Myunghoon Lee, Jae Hong Yoo, Ahyeon Jo, Kyung-Seok Han Category:3D Cell Models & Functional Assay Subcategory/cell type:Invasion assay/U-87MG Glioblastoma Cells Hydrogel:VitroGel® Hydrogel Matrix (Cat. No: VHM01) Glioblastoma (GBM) is a highly aggressive brain cancer known for its invasive nature, […]
VitroGel® Hydrogel Matrix was used to establish mobility, gelatinase activity, protein-protein interaction, and invasion assays to unravel the underlying mechanisms behind the invasiveness of Head and Neck Squamous Cell Carcinoma (HNSCC). Hydrogel:VitroGel® Hydrogel Matrix (Cat. No: VHM01) Head and neck squamous cell carcinoma (HNSCC) poses a significant global health challenge due to its high incidence […]
